Last reviewed 2026-04-22 · How we verify

GI medication

This is a gastrointestinal medication developed by East Carolina University, but specific mechanism details are not publicly available.

This is a gastrointestinal medication developed by East Carolina University, but specific mechanism details are not publicly available. Used for Gastrointestinal disorder (specific indication unknown).

At a glance

Mechanism of action

Without access to the specific drug name or identifier, the exact mechanism cannot be determined. GI medications typically work through various pathways such as acid suppression, motility enhancement, anti-inflammatory effects, or microbiome modulation depending on the therapeutic target.

Approved indications

• Gastrointestinal disorder (specific indication unknown)

Common side effects

No common side effects on file.

Key clinical trials

• An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis (PHASE2)
• Effect of Bismuth Subsalicylate on the Gut Microbiome and Host Response in Healthy Adults (PHASE1)
• Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery. (NA)
• Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF
• Gastroparesis Outcome Longitudinal Database Enrolled Numerically
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
• A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors (PHASE1)
• GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.